Abstract
Toward development of a safe and effective treatment for Alzheimer's disease, Elan Pharmaceuticals reported a novel -secretase inhibitor that specifically targets the cleavage of amyloid- precursor protein, opening the way to design of substrate-specific -secretase inhibitors that would reduce the amyloid burden without significant adverse events.
Original language | English (US) |
---|---|
Article number | 7 |
Journal | Alzheimer's Research and Therapy |
Volume | 3 |
Issue number | 2 |
DOIs | |
State | Published - 2011 |
ASJC Scopus subject areas
- Neurology
- Clinical Neurology
- Cognitive Neuroscience